APREMILAST TREATMENT AND LONG-TERM (UP TO 156 WEEKS) IMPROVEMENTS IN DACTYLITIS AND ENTHESITIS IN PATIENTS WITH PSORIATIC ARTHRITIS: ANALYSIS OF A LARGE DATABASE OF THE PHASE III CLINICAL DEVELOPMENT PROGRAM

Gladman DD, Kavanaugh A, Gomez-Reino JJ, Wollenhaupt J, Cutolo M, Schett G, Lespessailles E, Mcilraith M, Hu C, Edwards CJ, Birbara CA, Mease PJ (2017)

Publication Type: Conference contribution

Publication year: 2017

Journal

Annals of the Rheumatic Diseases BMJ Publishing Group

Book Volume: 76

Pages Range: 942-942

DOI: 10.1136/annrheumdis-2017-eular.3821

Authors with CRIS profile

Georg Schett Lehrstuhl für Innere Medizin III

Involved external institutions

University of Orléans / Université d'Orléans

France (FR) Celgene Corporation

United States (USA) (US) University of Massachusetts Amherst (UMass)

United States (USA) (US) Swedish Medical Center

United States (USA) (US) University Hospital Southampton NHS

United Kingdom (GB) Complejo Hospitalario Universitario de Santiago de Compostela

Spain (ES) Toronto Western Hospital

Canada (CA) University of California, San Diego

United States (USA) (US) University of Genova / Università degli Studi di Genova

Italy (IT) Schön Klinik Hamburg Eilbek

Germany (DE)

How to cite

APA:

Gladman, D.D., Kavanaugh, A., Gomez-Reino, J.J., Wollenhaupt, J., Cutolo, M., Schett, G.,... Mease, P.J. (2017). APREMILAST TREATMENT AND LONG-TERM (UP TO 156 WEEKS) IMPROVEMENTS IN DACTYLITIS AND ENTHESITIS IN PATIENTS WITH PSORIATIC ARTHRITIS: ANALYSIS OF A LARGE DATABASE OF THE PHASE III CLINICAL DEVELOPMENT PROGRAM. (pp. 942-942).

MLA:

Gladman, D. D., et al. "APREMILAST TREATMENT AND LONG-TERM (UP TO 156 WEEKS) IMPROVEMENTS IN DACTYLITIS AND ENTHESITIS IN PATIENTS WITH PSORIATIC ARTHRITIS: ANALYSIS OF A LARGE DATABASE OF THE PHASE III CLINICAL DEVELOPMENT PROGRAM." 2017. 942-942.

BibTeX: Download